Condensed Consolidated Statements of Cash Flow (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2026	Mar. 31, 2025
OPERATING ACTIVITIES
Net Income (Loss)	$ 169,695	$ (24,526)
Non-cash items:
Depreciation	11	330
Loss on impairment of leasehold improvements and lab equipment	0	2,811
Stock-based compensation expense	1,359	3,564
Change in fair value of contingent consideration	209	299
Non-cash royalty revenue	(181)	(448)
Non-cash interest expense	17	28
Net accretion and amortization of investments in marketable securities	(354)	(718)
Net change in operating items:
Accounts receivable	1,160	1,227
Increase (Decrease) in Accounts and Other Receivables	(178,741)	0
Prepaid expenses and other assets	(195)	413
Accounts payable and accrued liabilities	(985)	4,545
Change in deferred license revenue	0	(812)
Other liabilities	(105)	(104)
Net cash used in operating activities	(8,110)	(13,391)
INVESTING ACTIVITIES
Purchase of investments in marketable securities	(13,800)	(34,716)
Disposition of investments in marketable securities	16,000	46,065
Net cash provided by investing activities	2,199	11,349
FINANCING ACTIVITIES
Issuance of common shares pursuant to exercise of stock options	11,531	2,653
Issuance of common shares pursuant to ESPP	88	131
Net cash provided by financing activities	11,619	2,784
Effect of foreign exchange rate changes on cash and cash equivalents	(10)	4
Increase in cash and cash equivalents	5,698	746
Cash and cash equivalents, beginning of period	18,008	36,330
Cash and cash equivalents, end of period	$ 23,706	$ 37,076